Dulaglutide vs Survodutide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Dulaglutide
Once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes and cardiovascular risk reduction. Engineered as a GLP-1 analogue fused to a modified IgG4-Fc domain, which provides a ~5-day half-life and enables once-weekly subcutaneous dosing via a simple auto-injector pen with no reconstitution required.
Full profileSurvodutide
Survodutide is an investigational dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma. It pairs GLP-1's appetite suppression with glucagon-driven energy expenditure and hepatic fat oxidation — a mechanism especially promising for fatty-liver disease. It is not FDA-approved.
Full profile| Dulaglutide | Survodutide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Trulicity, LY2189265 | BI 456906, Glucagon/GLP-1 dual agonist, Zealand/Boehringer dual agonist |
| Evidence | FDA-approved | Investigational (in trials) |
| Dosing range | 0.75mg–4.5mg mg, once weekly subcutaneous | 0.3mg–6mg mg, once weekly subcutaneous |
| Administration | Subcutaneous injection (auto-injector pen) | Subcutaneous injection (weekly) |
| Key side effects | Nausea (most common), Diarrhea, Vomiting, Abdominal pain | Nausea (dose-dependent, during titration), Vomiting, Diarrhea, Decreased appetite |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Dulaglutide is fda-approved, while Survodutide is investigational (in trials).
- Administration: Dulaglutide — Subcutaneous injection (auto-injector pen); Survodutide — Subcutaneous injection (weekly).
How each works
Dulaglutide
Dulaglutide's large molecular structure (fusion with IgG4-Fc) prevents renal filtration and extends half-life via FcRn recycling, enabling once-weekly dosing. The REWIND cardiovascular outcomes trial demonstrated significant reduction in major adverse cardiovascular events (MACE) in patients with or at risk for cardiovascular disease, establishing dulaglutide as a cardioprotective agent beyond glucose control.
Survodutide
Survodutide activates both the glucagon receptor (increasing energy expenditure and liver fat oxidation) and the GLP-1 receptor (reducing appetite and slowing gastric emptying). Its Phase 3 SYNCHRONIZE-1 obesity trial met its primary endpoint with meaningful weight loss at 76 weeks, and survodutide holds FDA Breakthrough Therapy designation for non-cirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis. As of mid-2026 it remains investigational, with efficacy figures at the topline/conference stage.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.